Management of the Kotoka International Airport has revised safety precautionary measures it requires travelers to adhere to in the heat of the second wave of the much-dreaded Coronavirus.
According to the management of the facility, it intends to roll out the new precautionary measures effective Monday, February 8, 2021.
In a statement issued by KIA, all other passengers arriving in the country on international flights (including those arriving from the ECOWAS region) must not have symptoms suggestive of Covid-19 including but not limited to a body temperature of more than 38°C.
In addition, airlines that board passengers without PCR test results or transport passengers with positive PCR test results into the country will be fined a sum of US$3,500 per passenger.
“Non-Ghanaians may be refused entry and returned to the point of embarkation at a cost to the Airline.
“Ghanaians will be allowed entry but subject to 14 days of mandatory quarantine at a designated facility,” the statement read.
The cost of PCRs is now US$50 for Ghanaians and ECOWAS citizens and US$150 for all other passengers.
However, airline crew, children under five years, passengers who arrive under emergency circumstances such as diverted flights will not be required to undergo testing if they do not leave the airport or remain in isolation in their hotel.
For passengers departing the country, they are required to adhere to Covid-19 testing requirements for their destination countries.
KIA, however, encourages the use of the online check-in or self-service kiosk in order to reduce physical contact.
In other news, South Africa has taken delivery of the first batch of AstraZeneca, e supposed Covid-19 vaccines that are expected to help the country stem its efforts against the Coronavirus disease.
An Emirates flight carrying 1 million AstraZeneca vaccine doses touched down at the OR Tambo International Airport on Monday afternoon on South African soil. President Cyril Ramaphosa was there to receive and inspect the shipment before tracks hauled it away to the laboratories of the country’s medicines regulator where the vaccines will undergo further efficacy tests before being deployed.
By Edwin Abanga